← Back to Clinical Trials
Recruiting NCT04426214

Neuromodulation and Cognitive Training for Substance Use Disorders

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Stimulant Use
Sponsor University of Minnesota
Study Type INTERVENTIONAL
Phase N/A
Enrollment 80
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2021-07-16
Completion 2026-09-01
Interventions
tDCSCognitive Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve treatment outcomes.

Eligibility Criteria

Inclusion Criteria: * Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 3 weeks at study enrollment * Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study. * Able to provide written consent and comply with study procedures. * Meets the MINI 7 diagnostic criteria for either stimulant use disorder (SUD) or alcohol use disorder (AUD). Exclusion Criteria: * Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, HIV) * Over 9 months of abstinence from substance use * A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI) * Presence of a condition that would render study measures difficult or impossible to administer or interpret * Age outside the range of 18 to 65 * Primary current substance use disorder diagnosis (according to MINI 7 diagnostic criteria) for a substance other than stimulant or alcohol, except for

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}